PSG
7.4.2021 09:02:09 CEST | Business Wire | Press release
Imaweb, a leading independent developer and provider of automotive and dealership software solutions in Europe, today announced the acquisition of Stieger, a leading dealership software solutions provider in Switzerland and Austria. Imaweb is backed by PSG, a growth equity firm that focuses on partnering with middle-market software and technology-enabled service companies.
Headquartered in Staad, Switzerland, Stieger simplifies client processes and improves efficiency for original equipment manufacturers (“OEMs”) and dealerships through its innovative software solutions. Founded in 1982, the company currently employs around 60 people across six locations in Switzerland, Austria and Slovakia. Stieger clients include Swiss and Austrian franchise dealers across a number of OEM brands, such as Volkswagen, Audi, Renault, Ford, Toyota, Peugeot, Volvo, Mercedes and Citroën.
The acquisition of Stieger will strengthen Imaweb’s presence in DACH, the largest automotive market in Europe, and Stieger’s market leading positions in Switzerland and Austria will complement Imaweb’s existing presence in Germany. Furthermore, Stieger’s product offering is additive to Imaweb’s digital software solutions which support the digitalisation of the overall customer journey for dealerships and OEMs. Following the transaction, Stieger’s CEO and Founder Eugen Stieger will retire from the business.
“We are delighted to onboard Stieger as part of Imaweb,” said Patrick Prajs, CEO of Imaweb. “We believe that the company’s innovative technology will bring an added edge to our existing offering to OEMs and dealerships across Europe.”
Julian Ciccale, Co-Founder and Deputy CEO of Imaweb, added, “The acquisition of Stieger also supports our pan-European growth strategy by strengthening our presence in the DACH region, which is a priority market for Imaweb.”
Eugen Stieger, CEO and Founder of Stieger, said, “In Imaweb, we believe we’ve found the right partner to take Stieger forward and ensure the company’s continued success over the coming years. The Stieger team are excited to join Imaweb as the company enters the next phase of its growth.”
PSG invested in Imaweb in May 2019, backing the company’s founders to seek to transform the leading automotive CRM solutions provider in Spain into a pan-European player. Since then, Imaweb has grown quickly through a combination of organic growth and strategic M&A. This transaction is Imaweb’s third in 2021, following the acquisitions of leading German automotive digital software solutions provider Procar in January and Stampyt, a leading French AI-driven remarketing software provider, in March. Imaweb now offers a full suite of digital software solutions designed for car dealers and OEMs throughout Europe.
The financial terms of this acquisition are not being disclosed.
Imaweb
Imaweb is a leading developer and provider of digital solutions for the automotive sector in Europe. The company was formed through the merger of Imaweb, a Spanish company dedicated to developing global customer management solutions for sales, marketing and after-sales, and DATAFIRST-I’Car Systems group, a French software development company for car manufacturers, group distributers and dealers, in 2019. For more information, visit https://www.imaweb.com/ .
Stieger
Stieger Software is a leading developer of complete IT solutions and interfaces for the Swiss and Austrian automotive industries. Founded in 1982, the company now employs around 60 highly qualified people across six locations in three countries. Stieger's innovative dealer management systems are currently used by more than 1650 customers.
Stieger has a threefold core business: a cutting-edge specialty in the automotive industry, a la carte concepts and a systematic standardization policy for software use. For more information about the company, please visit https://www.stieger.ch
PSG
PSG is a growth equity firm that partners with middle-market software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 65 companies and facilitated over 275 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City and London. https://www.psgequity.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom